Literature DB >> 22811856

Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis.

Xiaohong Jiang1, Sai Yi Pan, Margaret de Groh, Shiliang Liu, Howard Morrison.   

Abstract

BACKGROUND/AIMS: Our study aimed to assess 1) the temporal trends in incidence and mortality of liver cancer and 2) age-period-cohort effects on the incidence in Canada.
METHODS: We analyzed data obtained from the Canadian Cancer Registry Database and Canadian Vital Statistics Death Database. We first examined temporal trends by sex, age group, and birth cohort between 1972 and 2006. Three-year period rates and annual percentage change (APC) were calculated to compare the changes over the study period. We used age-period-cohort modelling to estimate underlying effects on the observed trends in incidence.
RESULTS: The overall age-adjusted incidence rates increased from 2.6 and 1.5 per 100 000 in 1972-74 to 6.5 (APC: 2.9) and 2.2 (APC: 1.2) per 100 000 in 2004-06 among males and females, respectively. The age-adjusted mortality rates increased from 3.3 and 2.0 per 100 000 in 1972-74 to 6.0 (APC: 2.3) and 2.6 (APC: 1.2) per 100 000 in 2004-06 among males and females, respectively. The incidence increased most rapidly in men aged 45-54 years (APC: 4.1) and women aged 65-74 years (APC: 1.7) over the period of study.
CONCLUSIONS: The age-period-cohort analysis suggests that birth-cohort effect is underlying the increase in incidence. While the exact reason for the increased incidence of liver cancer remains unknown, reported increase in HBV and HCV infections, and immigration from high-risk regions of the world may be important factors.

Entities:  

Keywords:  HBV and HCV; Incidence of liver cancer; age-period-cohort model; immigration

Year:  2011        PMID: 22811856      PMCID: PMC3397630          DOI: 10.3978/j.issn.2078-6891.2011.024

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  37 in total

1.  An update on cancer survival.

Authors:  Larry F Ellison; Kathryn Wilkins
Journal:  Health Rep       Date:  2010-09       Impact factor: 4.796

2.  International Classification of Diseases: eighth revision.

Authors:  I M Moriyama
Journal:  WHO Chron       Date:  1968-02

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men.

Authors:  M W Yu; Y C Yang; S Y Yang; S W Cheng; Y F Liaw; S M Lin; C J Chen
Journal:  J Natl Cancer Inst       Date:  2001-11-07       Impact factor: 13.506

Review 5.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Epidemiology of hepatocellular carcinoma in Canada, 1995: analysis of death certificates.

Authors:  Susie ElSaadany; Antonio Giulivi
Journal:  Chronic Dis Can       Date:  2006

7.  Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis.

Authors:  Gaia Pocobelli; Linda S Cook; Rollin Brant; Samuel S Lee
Journal:  Liver Int       Date:  2008-04-01       Impact factor: 5.828

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  An epidemiologic study of effects of alcohol in the liver in hepatitis B surface antigen carriers.

Authors:  H Nomura; S Kashiwagi; J Hayashi; W Kajiyama; H Ikematsu; A Noguchi; S Tani; M Goto
Journal:  Am J Epidemiol       Date:  1988-08       Impact factor: 4.897

10.  Cluster of liver cancer and immigration: a geographic analysis of incidence data for Ontario 1998-2002.

Authors:  Yue Chen; Qilong Yi; Yang Mao
Journal:  Int J Health Geogr       Date:  2008-06-02       Impact factor: 3.918

View more
  7 in total

1.  Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation.

Authors:  Juan Li; Junru Liu; Beihui Huang; Dong Zheng; Mei Chen; Zhenhai Zhou; Duorong Xu; Waiyi Zou
Journal:  Tumour Biol       Date:  2013-02-23

Review 2.  Disease Burden of Hepatocellular Carcinoma: A Global Perspective.

Authors:  Mehmet Sayiner; Pegah Golabi; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

3.  Proton therapy for hepatocellular carcinoma.

Authors:  Ted C Ling; Joseph I Kang; David A Bush; Jerry D Slater; Gary Y Yang
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

4.  Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.

Authors:  Jianguo Zhou; Tao Yan; Xinyu Bi; Hong Zhao; Zhen Huang; Yefan Zhang; Yuan Li; Li Feng; Jing Wang; Jianqiang Cai
Journal:  Tumour Biol       Date:  2013-01-16

5.  Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems.

Authors:  Chang Liu; Li-gen Duan; Wu-sheng Lu; Lu-nan Yan; Guang-qin Xiao; Li Jiang; Jian Yang; Jia-yin Yang
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

6.  Long-Term Trends of Liver Cancer Incidence and Mortality in China 1990-2017: A Joinpoint and Age-Period-Cohort Analysis.

Authors:  Fang Wang; Sumaira Mubarik; Yu Zhang; Lu Wang; Yafeng Wang; Chuanhua Yu; Hao Li
Journal:  Int J Environ Res Public Health       Date:  2019-08-12       Impact factor: 3.390

7.  MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.

Authors:  Jennifer Sammon; Sandra Fischer; Ravi Menezes; Hooman Hosseini-Nik; Sara Lewis; Bachir Taouli; Kartik Jhaveri
Journal:  Cancer Imaging       Date:  2018-02-27       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.